Venus Remedies Limited has announced a significant development within its promoter group structure, disclosing information about an approved merger between two key promoter group entities. The pharmaceutical company received formal communication on March 2, 2026, regarding the corporate restructuring initiative.

Merger Details and Structure

The disclosure pertains to a Scheme of Amalgamation between Sunev Pharma Solutions Private Limited and Spine Software Systems Private Limited, both promoter group entities of Venus Remedies. Under the approved scheme, Sunev will merge with and into Spine, creating a consolidated entity within the promoter group structure.

Shareholding Impact and Transfer

The merger carries significant implications for Venus Remedies' shareholding structure. Sunev Pharma Solutions currently holds 17.21% of Venus Remedies' equity share capital, representing a substantial stake in the pharmaceutical company. Upon the scheme becoming effective, this entire shareholding will vest in Spine Software Systems.

Corporate Control and Governance

Venus Remedies has emphasized that this transaction represents an internal promoter group restructuring exercise. The company has clarified that the merger will not result in any change of control, maintaining the existing governance structure and management oversight.

Key aspects of the restructuring include:

• Unchanged Control Structure: The merger will not alter the control dynamics of Venus Remedies
• Stable Shareholding: Aggregate promoter and promoter group shareholding in Venus Remedies will remain unchanged
• Internal Reorganization: The transaction is characterized as an internal restructuring within the promoter group

Regulatory Compliance and Disclosure

The disclosure was made pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, demonstrating Venus Remedies' commitment to regulatory compliance and transparency. The company received the communication on March 2, 2026, from both promoter group entities confirming their respective board approvals for the merger scheme.

The implementation of the scheme remains subject to obtaining necessary statutory and regulatory approvals, which is standard procedure for such corporate restructuring transactions. Venus Remedies has requested stakeholders to take note of this information as part of its ongoing disclosure obligations.

Venus Remedies has announced its unaudited financial results for the third quarter ended December 31, 2025, showcasing robust profitability growth and steady operational performance. The pharmaceutical company's latest quarterly results demonstrate improved financial metrics across key parameters.

Financial Performance Overview

The company's consolidated financial results for the third quarter show significant improvement in bottom-line performance, with net profit witnessing substantial growth while revenue maintained steady momentum.

Profitability Analysis

The standout feature of Venus Remedies' quarterly performance has been the remarkable 30.51% year-on-year growth in consolidated net profit after tax, rising to ₹25.58 crore from ₹19.60 crore in the corresponding quarter of the previous year. This substantial increase in profitability indicates enhanced operational efficiency and better cost management strategies.

Nine-Month Performance

For the nine-month period ended December 31, 2025, the company demonstrated consistent growth momentum. Income from operations reached ₹510.19 crore compared to ₹455.23 crore in the previous year, representing a growth of 12.07%. Net profit after tax for the nine-month period stood at ₹55.31 crore, significantly higher than ₹24.34 crore in the corresponding period last year.

Regulatory Compliance

The financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on January 29, 2026. The results were filed with stock exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. Complete financial results are available on BSE, NSE, and the company's official website.